- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04329624
Effect Levosimendan Administration on Postoperative NT-proBNP in Cardiac Risk Patients (IMPROVE)
The Effect of Perioperative LevosIMendan Administration on Postoperative N-terminal pRo Brain Natriuretic Peptide Concentration in Patients With Increased cardiOVascular Risk Factors Undergoing Noncardiac surgEry - A Double-blinded Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Christian Reiterer, MD
- Phone Number: 20760 004340400
- Email: christian.reiterer@meduniwien.ac.at
Study Contact Backup
- Name: Edith Fleischmann, MD
- Phone Number: 41020 004340400
- Email: edith.fleischmann@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1100
- Medical University of Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All patients need to meet all of the following criteria for inclusion (1-4):
- Undergoing major surgery planned for more than 2 hours
- ≥ 65 years of age and ≤ 85 years of age
- Provide written informed consent AND
- Fulfill ≥ 2 of the following criteria (A-E)
A) NT-proBNP ≥ 200 ng/L
B) History of coronary artery disease defined as 1 of the following 7 criteria (I to VII):
- I) History of angina
- II) History of myocardial infarction or acute coronary syndrome
- III) History of a segmental cardiac wall motion abnormality on echocardiography/radionuclide imaging
- IV) History of positive myocardial stress test (echocardiographic or radionuclide)
- V) History of a coronary artery stenosis > 50%
- VI) ECG with pathological Q waves in any two contiguous leads
- VII) History of previous artery revascularizations
C) History of permanent/paroxysmal atrial fibrillation diagnosed by physician/specialist
D) History of peripheral arterial disease as defined by a physician/specialist diagnosis of a current, or prior history of any 1 of the following 5criteria (I-V)
- I) Intermittent claudication
- II) Stenosis ≥ 70 % detected by angiography or doppler
- III) Stenosis ≤ 70% detected by angiography or doppler AND requiring medical treatment e.g. ASA or other platelet inhibitor
- IV) History of stroke or TIA - diagnosed by physician or CT/MRI
- V) Diagnosed cerebral arteriovascular disease (cAVK) diagnosed by a physician/specialist
E) Any 3 of 10 of the following risk criteria (i - x).
- i. History of congestive heart failure defined as a physician diagnosis of a current or prior episode of congestive heart failure OR prior radiographic evidence of vascular redistribution, interstitial pulmonary edema, or frank alveolar pulmonary edema;
- ii. History of a transient ischemic attack;
- iii. Diabetes and currently taking an oral hypoglycemic agent or insulin;
- iv. History of hypertension;
- v. Hyperlipidemia and currently taking a lipid lowering agent;
- vi. Documented chronic kidney disease diagnosed by physician/specialist and creatinine clearance > 30 ml/min
- vii. History of smoking within 2 years of surgery
- viii. Diastolic dysfunction (≥ grade 1) documented by echocardiography
- ix. Age ≥ 70 years
- x. Preoperative Troponin T (5th generation) ≥ 25ng/dL
Exclusion Criteria:
A) Previous adverse response and/or allergy to levosimendan B) ICU Patients undergoing surgery C) Preoperative Sepsis/SIRS needing ICU treatment D) Preoperative hemodynamically instable patients, who requirevasopressor or inotropic support E) Renal or liver transplantation F) History of severe heart failure (e.g. LVEF < 30%) G) Patients undergoing surgery for pheochromocytoma H) Liver cirrhosis I) Pulmonary hypertension (mPAP > 25 mmHg) J) Severe Renal Failure defines as creatinine clearance ≤ 30ml/min
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Levosimendan
Patients receive a continuous infusion of 12.5mg solved in 50mL Levosimendan for up to 24 hours.
Infusion will be started with surgical skin incision.
|
Levosimendan 2.5 mg/ml injection contains levosimendan 2.5 mg, povidone 10.0 mg, citric acid, anhydrous 2.0 mg and ethanol, anhydrous to 1.0 mL.
Levosimendan injection is a clear, yellow to orange solution.
Immediately after skin incision patients allocated to the verum group will receive a dose of 12.5 mg in 500 mL of levosimendan.
|
Placebo Comparator: Placebo
Patients receive a continuous infusion containing a placebo solved in 50mL for up to 24 hours.
Infusion will be started with surgical skin incision.
|
Placebo 2.5 mg/ml injection contains riboflavine sodium phosphate 0.4 mg, dehydrated alcohol 100 mg and water for injection to 1 mL. Immediately after skin incision patients allocated to the placebo group will receive 500 mL of 5% Glucose. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative maximum NT-proBNP concentration
Time Frame: First 5 Postoperative Days
|
The administration of levosimendan improves LVEF and myocardial oxygen perfusion, which will be reflected in a decrease of postoperative NT-proBNP concentration.Since NT-proBNP is a strong predictor for postoperative cardiovascular complications in patients undergoing noncardiac surgery, we want to test the efficiency of levosimendan to decrease postoperative maxNT-proBNP concentrations in patients with increased cardiac risk factors undergoing moderate- to high-risk noncardiac surgery.
|
First 5 Postoperative Days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Postoperative maximum troponin T concentration
Time Frame: First five postoperative days
|
Levosimendan improves myocardial perfusion and might therefore reduce the postoperative maximum rise in TnT
|
First five postoperative days
|
Incidence of MINS (myocardial injury in non cardiac surgery)
Time Frame: First three postoperative days
|
Levosimendan decreases the incidence of MINS during the first 3 postoperative days as compared to placebo in patients with increased cardiovascular risk factors undergoing moderateto high-risk noncardiac surgery.
MINS is defined as: (i) a non-high-sensitivity troponin T >_30ng/L2 and (ii) a high-sensitivity troponin T (hsTnT) of 20 to <65 ng/L with an absolute change of at least 5 ng/L-this change threshold is independently associated with 30-day mortality [hazard ratio (HR) 4.69; 95% confidence interval (CI) 3.52-6.25]-or
an hsTnT level >_65ng/ L. Furthermore, an absolute change of at least 5 ng/L is independently associated with 30-day mortality and will also be defined as MINS.
TnT will be measured within 2 hours after surgery, on the first, second and third postoperative day.
|
First three postoperative days
|
Myocardial Infarction
Time Frame: 30 days and 1 year after surgery
|
Levosimendan reduces the event rates of myocardial infarction and death during 30 days and 1 year after surgery as compared to placebo.
Myocardial infarction is defined as a rise of TnT at least one value is above the 99th percentile URL and with at least one of the following: (i) symptoms of acute myocardial ischaemia; (ii) new ischaemic ECG changes; (iii) development of pathological Q waves; (iiii) imaging evidence of new loss of viable myocardium; (v) new regional wall motion abnormality in a pattern consistent with an ischemic ethiology; (vi) identification of a coronary thrombus by angiography including intracoronary imaging or autopsy.
|
30 days and 1 year after surgery
|
Disability
Time Frame: 30 days and 1 year after surgery
|
We evaluate the WHODAS 2.0 score before surgery on the day of consent, 30 days after surgery, and 1 year after surgery per phone call. For analyzing we use simply scoring. Each score is assigned to each of the following items - "none" (0), "mild" (1), "moderate" (2), "severe" (3), and "extreme (4). We will simply add up the scores from the items without recoding or collapsing of response categories, thus, there is no weighting of the individual items. As a result, the simple sum of the scores of the items across all domains constitutes a statistic that is sufficient to describe the degree of functional limitations. |
30 days and 1 year after surgery
|
NT-proBNP Mortality
Time Frame: 30 days and 1 year after surgery
|
Perioperative NT-proBNP elevations are associated with postoperative mortality, cardiac mortality, mortality and nonfatal MI, and cardiac failure at both 30 days and 180 days or more after surgery. NT-proBNP values have been stratified to the previous published thresholds to predict mortality or MI after surgery. |
30 days and 1 year after surgery
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sub-Study I: Fluid status determination
Time Frame: within 5 days after surgery
|
Bioimpedance spectroscopy to determine perioperative fluid status including: 1) over hydration and total body water
|
within 5 days after surgery
|
Sub-Study II: Acute Kidney Injury
Time Frame: within 5 days after surgery
|
The number of patients developing acute kidney injury after and the number of patients requiring renal replacement therapy after surgery.
|
within 5 days after surgery
|
Sub-Study III: Inflammatory Response
Time Frame: within 5 days after surgery
|
Effect of levosimendan on postoperative maximum Interleukin 6 and CRP concentrations.
|
within 5 days after surgery
|
Sub-Study IV: Neurocognitive decline
Time Frame: within first 5 postoperative days and 1 year after surgery
|
Effect of levosimendan on postoperative neurocognitive decline assess using MoCA
|
within first 5 postoperative days and 1 year after surgery
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Sessler DI, Meyhoff CS, Zimmerman NM, Mao G, Leslie K, Vasquez SM, Balaji P, Alvarez-Garcia J, Cavalcanti AB, Parlow JL, Rahate PV, Seeberger MD, Gossetti B, Walker SA, Premchand RK, Dahl RM, Duceppe E, Rodseth R, Botto F, Devereaux PJ. Period-dependent Associations between Hypotension during and for Four Days after Noncardiac Surgery and a Composite of Myocardial Infarction and Death: A Substudy of the POISE-2 Trial. Anesthesiology. 2018 Feb;128(2):317-327. doi: 10.1097/ALN.0000000000001985.
- Duceppe E, Parlow J, MacDonald P, Lyons K, McMullen M, Srinathan S, Graham M, Tandon V, Styles K, Bessissow A, Sessler DI, Bryson G, Devereaux PJ. Canadian Cardiovascular Society Guidelines on Perioperative Cardiac Risk Assessment and Management for Patients Who Undergo Noncardiac Surgery. Can J Cardiol. 2017 Jan;33(1):17-32. doi: 10.1016/j.cjca.2016.09.008. Epub 2016 Oct 4. Erratum In: Can J Cardiol. 2017 Dec;33(12 ):1735.
- Rodseth RN, Biccard BM, Le Manach Y, Sessler DI, Lurati Buse GA, Thabane L, Schutt RC, Bolliger D, Cagini L, Cardinale D, Chong CP, Chu R, Cnotliwy M, Di Somma S, Fahrner R, Lim WK, Mahla E, Manikandan R, Puma F, Pyun WB, Radovic M, Rajagopalan S, Suttie S, Vanniyasingam T, van Gaal WJ, Waliszek M, Devereaux PJ. The prognostic value of pre-operative and post-operative B-type natriuretic peptides in patients undergoing noncardiac surgery: B-type natriuretic peptide and N-terminal fragment of pro-B-type natriuretic peptide: a systematic review and individual patient data meta-analysis. J Am Coll Cardiol. 2014 Jan 21;63(2):170-80. doi: 10.1016/j.jacc.2013.08.1630. Epub 2013 Sep 26.
- Rodseth RN, Biccard BM, Chu R, Lurati Buse GA, Thabane L, Bakhai A, Bolliger D, Cagini L, Cahill TJ, Cardinale D, Chong CP, Cnotliwy M, Di Somma S, Fahrner R, Lim WK, Mahla E, Le Manach Y, Manikandan R, Pyun WB, Rajagopalan S, Radovic M, Schutt RC, Sessler DI, Suttie S, Vanniyasingam T, Waliszek M, Devereaux PJ. Postoperative B-type natriuretic peptide for prediction of major cardiac events in patients undergoing noncardiac surgery: systematic review and individual patient meta-analysis. Anesthesiology. 2013 Aug;119(2):270-83. doi: 10.1097/ALN.0b013e31829083f1.
- Reiterer C, Kabon B, Taschner A, Adamowitsch N, Graf A, Fraunschiel M, Horvath K, Kuhrn M, Clement T, Treskatsch S, Berger C, Fleischmann E. Effect of perioperative levosimendan administration on postoperative N-terminal pro-B-type natriuretic peptide concentration in patients with increased cardiovascular risk factors undergoing non-cardiac surgery: protocol for the double-blind, randomised, placebo-controlled IMPROVE trial. BMJ Open. 2022 Jan 21;12(1):e058216. doi: 10.1136/bmjopen-2021-058216.
- Writing Committee for the VISION Study Investigators; Devereaux PJ, Biccard BM, Sigamani A, Xavier D, Chan MTV, Srinathan SK, Walsh M, Abraham V, Pearse R, Wang CY, Sessler DI, Kurz A, Szczeklik W, Berwanger O, Villar JC, Malaga G, Garg AX, Chow CK, Ackland G, Patel A, Borges FK, Belley-Cote EP, Duceppe E, Spence J, Tandon V, Williams C, Sapsford RJ, Polanczyk CA, Tiboni M, Alonso-Coello P, Faruqui A, Heels-Ansdell D, Lamy A, Whitlock R, LeManach Y, Roshanov PS, McGillion M, Kavsak P, McQueen MJ, Thabane L, Rodseth RN, Buse GAL, Bhandari M, Garutti I, Jacka MJ, Schunemann HJ, Cortes OL, Coriat P, Dvirnik N, Botto F, Pettit S, Jaffe AS, Guyatt GH. Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. JAMA. 2017 Apr 25;317(16):1642-1651. doi: 10.1001/jama.2017.4360.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- IMPROVE_2.2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Risk Factor
-
University of Southern DenmarkRegion of Southern Denmark; Odense Patient Data Explorative Network; ENIGMA Solutions... and other collaboratorsActive, not recruitingCardiovascular Risk Factor | Risk CommunicationDenmark
-
University of Split, School of MedicineCompletedCardiovascular Risk Factor | Lifestyle Risk ReductionCroatia
-
University Hospital, BrestRecruiting
-
University Hospitals Cleveland Medical CenterRecruitingCardiovascular Risk FactorUnited States
-
Northwestern UniversityNorthShore University HealthSystem; Case Western Reserve University; Shirley... and other collaboratorsCompleted
-
University of ArizonaTerminatedCardiovascular Risk FactorUnited States
-
Penn State UniversityCompletedCardiovascular Risk FactorUnited States
-
Clinique BizetCompleted
-
University Hospital, BrestCompleted
-
University of DelawareCompleted
Clinical Trials on Levosimendan
-
Central Hospital, Nancy, FranceRecruitingCardiac Surgery | Heart Failure With Reduced Ejection Fraction | LevosimendanFrance
-
National Taiwan University HospitalUnknown
-
Assistance Publique - Hôpitaux de ParisRecruitingCardiogenic Shock | Extracorporeal Membrane Oxygenation ComplicationFrance
-
Aretaieion University HospitalCompletedHypertension, Pulmonary | Pulmonary Vascular Resistance Abnormality | Cardiac FailureGreece
-
Aretaieion University HospitalCompletedCardiac Surgery | Cardiac Disease | Cardiac Failure | Inotropes | Ejection FractionGreece
-
Orion Corporation, Orion PharmaCompletedAmyotrophic Lateral SclerosisCanada, United States, Australia, Austria, United Kingdom, Germany, Finland, Spain, France, Italy, Sweden, Netherlands, Belgium, Ireland
-
Orion Corporation, Orion PharmaCompletedAmyotrophic Lateral SclerosisIreland, Netherlands, United Kingdom, Germany
-
Cancer Institute and Hospital, Chinese Academy...RecruitingHead and Neck Squamous Cell CarcinomaChina
-
Tenax Therapeutics, Inc.CompletedHeart Failure With Normal Ejection Fraction | Heart Failure, Right Sided | Hypertension Pulmonary SecondaryUnited States
-
Dr. Gerhard PölzlOrion Corporation, Orion PharmaUnknown